Brokers Issue Forecasts for Baxter International Inc.’s Q3 2017 Earnings (NYSE:BAX)

Baxter International Inc. (NYSE:BAX) – Stock analysts at Leerink Swann raised their Q3 2017 EPS estimates for Baxter International in a research report issued on Wednesday. Leerink Swann analyst D. Antalffy now forecasts that the medical instruments supplier will post earnings per share of $0.59 for the quarter, up from their previous estimate of $0.54. Leerink Swann currently has a “Outperform” rating and a $75.00 price target on the stock. Leerink Swann also issued estimates for Baxter International’s Q3 2018 earnings at $0.66 EPS, Q4 2018 earnings at $0.70 EPS and FY2020 earnings at $3.32 EPS.

Baxter International (NYSE:BAX) last released its earnings results on Wednesday, July 26th. The medical instruments supplier reported $0.63 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.06. The firm had revenue of $2.61 billion during the quarter, compared to analysts’ expectations of $2.59 billion. Baxter International had a net margin of 8.85% and a return on equity of 15.09%. The business’s quarterly revenue was up .8% compared to the same quarter last year. During the same period in the prior year, the company earned $0.46 EPS.

COPYRIGHT VIOLATION WARNING: This piece of content was published by Transcript Daily and is owned by of Transcript Daily. If you are viewing this piece of content on another domain, it was stolen and republished in violation of U.S. & international trademark and copyright legislation. The original version of this piece of content can be accessed at https://transcriptdaily.com/2017/08/13/brokers-issue-forecasts-for-baxter-international-inc-s-q3-2017-earnings-nysebax-updated.html.

BAX has been the subject of several other research reports. Zacks Investment Research raised Baxter International from a “hold” rating to a “strong-buy” rating and set a $64.00 price objective for the company in a report on Monday, May 1st. Morgan Stanley lifted their price objective on Baxter International from $48.00 to $52.00 and gave the stock an “underweight” rating in a report on Friday, April 28th. Goldman Sachs Group, Inc. (The) reissued a “conviction-buy” rating and set a $71.00 price target on shares of Baxter International in a report on Tuesday, May 16th. UBS AG boosted their price target on Baxter International from $57.00 to $62.00 and gave the company a “neutral” rating in a report on Friday, July 28th. Finally, Barclays PLC boosted their price target on Baxter International from $64.00 to $70.00 and gave the company an “overweight” rating in a report on Thursday, July 27th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $65.33.

Baxter International (NYSE BAX) opened at 60.71 on Monday. The company’s 50-day moving average is $60.72 and its 200 day moving average is $54.77. Baxter International has a 1-year low of $43.13 and a 1-year high of $63.14. The firm has a market capitalization of $33.01 billion, a PE ratio of 36.84 and a beta of 0.66.

A number of large investors have recently modified their holdings of BAX. Canada Pension Plan Investment Board increased its stake in shares of Baxter International by 16.1% in the second quarter. Canada Pension Plan Investment Board now owns 1,040,554 shares of the medical instruments supplier’s stock worth $62,995,000 after buying an additional 144,400 shares during the period. Cigna Investments Inc. New increased its stake in shares of Baxter International by 8.7% in the second quarter. Cigna Investments Inc. New now owns 21,494 shares of the medical instruments supplier’s stock worth $1,305,000 after buying an additional 1,723 shares during the period. BP PLC increased its stake in shares of Baxter International by 118.8% in the second quarter. BP PLC now owns 151,000 shares of the medical instruments supplier’s stock worth $9,140,000 after buying an additional 82,000 shares during the period. Advisor Partners LLC increased its stake in shares of Baxter International by 21.5% in the second quarter. Advisor Partners LLC now owns 13,574 shares of the medical instruments supplier’s stock worth $822,000 after buying an additional 2,398 shares during the period. Finally, Baker Ellis Asset Management LLC bought a new stake in shares of Baxter International during the second quarter worth about $109,000. Institutional investors and hedge funds own 84.21% of the company’s stock.

In other Baxter International news, Director Carole J. Shapazian sold 3,760 shares of the company’s stock in a transaction that occurred on Tuesday, May 9th. The stock was sold at an average price of $55.89, for a total transaction of $210,146.40. Following the sale, the director now directly owns 16,226 shares in the company, valued at $906,871.14. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Carole J. Shapazian sold 2,618 shares of the company’s stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $57.92, for a total value of $151,634.56. Following the sale, the director now owns 9,848 shares in the company, valued at $570,396.16. The disclosure for this sale can be found here. Insiders sold 137,110 shares of company stock worth $7,642,246 over the last quarter. 0.05% of the stock is owned by company insiders.

The company also recently announced a quarterly dividend, which will be paid on Monday, October 2nd. Investors of record on Friday, September 1st will be given a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, August 30th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 1.05%. Baxter International’s dividend payout ratio is currently 38.79%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Earnings History and Estimates for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply